Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BridgeBio Pharma, Inc. BBIO
$13.60
-$0.63 (-4.63%)
На 18:01, 12 мая 2023
+32.35%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2303991740.00000000
-
week52high
19.95
-
week52low
4.98
-
Revenue
77648000
-
P/E TTM
-4
-
Beta
0.70862000
-
EPS
-3.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Buy | Buy | 24 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 26 июл 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 06 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 16 мар 2022 г. |
| JP Morgan | Overweight | Overweight | 18 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kumar Neil | D | 1492722 | 120000 | 05 янв 2023 г. |
| STEPHENSON BRIAN C | D | 280224 | 61040 | 05 янв 2023 г. |
| Kumar Neil | D | 995686 | 200000 | 21 дек 2022 г. |
| STEPHENSON BRIAN C | D | 341264 | 19678 | 17 ноя 2022 г. |
| Kumar Neil | D | 4813197 | 34640 | 17 ноя 2022 г. |
| STEPHENSON BRIAN C | D | 11358 | 3786 | 16 ноя 2022 г. |
| STEPHENSON BRIAN C | D | 120965 | 24193 | 16 ноя 2022 г. |
| STEPHENSON BRIAN C | D | 7003 | 778 | 16 ноя 2022 г. |
| STEPHENSON BRIAN C | D | 10259 | 1710 | 16 ноя 2022 г. |
| STEPHENSON BRIAN C | D | 360942 | 10789 | 16 ноя 2022 г. |
Новостная лента
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
GlobeNewsWire
27 апр 2023 г. в 07:30
PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas, NV on Wednesday, May 10 at 10:00 am PT.
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
24/7 Wall Street
10 апр 2023 г. в 22:58
March was a good month for the stock market, with the S&P 500 gaining about 3.5%.
2 Best Growth Stocks to Buy in April
The Motley Fool
03 апр 2023 г. в 10:00
Growth stocks have been under heavy pressure over the past year. A handful of biotech companies have defied this broader downturn, however.
Bridgebio shares surge on takeout target hopes
CNBC Television
29 мар 2023 г. в 15:14
CNBC's Meg Tirrell joins 'Power Lunch' to report on Bridgebio's stock surge and pharma returns.
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?
Zacks Investment Research
27 мар 2023 г. в 06:56
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.